ALK Positive's Research Priorities - April 21, 2024 ALKtALK

ALK Positive Inc (API) has a sense of urgency that drives our work toward the discovery and deployment of even better, and ultimately curative, treatments for ALK-positive cancer. Watch this ALKtALK to hear our own Drs Ken Culver and Marc Muskavitch highlight how API is advocating with industry and medical professionals to prioritize ALK research. Ken and Marc also discuss the initiatives we’re backing with our valuable research dollars to accelerate research and bring new treatment opportunities to ALK-positive cancer patients. Not to be missed.